Capricor FDA Review Extension and Securities Class Action

Paragon Therapeutics, a biotechnology company developing deramiocel for Duchenne muscular dystrophy, faces a securities class action lawsuit and regulatory setbacks. The FDA extended the PDUFA target action date for deramiocel from August 22, 2026 to November 22, 2026, classifying Capricor's submission as a major amendment. This follows a July 2026 Advisory Committee meeting where the FDA published briefing documents revealing unagreed-upon post-hoc modifications to the pre-specified statistical analysis plan (SAP). The FDA stated the HOPE-3 study did not meet its pre-specified primary and secondary efficacy endpoints, and the Advisory Committee voted 9-3 against efficacy. Capricor's stock crashed 64% on July 27, 2026. The class action alleges material misleading statements regarding clinical trial data and SAP changes, with a lead plaintiff deadline of September 28, 2026. Capricor reported a Q2 2026 net loss of $40.7 million and skipped analyst Q&A on its earnings call.